Questions Linger on Initiating and Switching HIV Treatment When and how to start antiretroviral therapy—and how to respond down the line when changes become necessary—remain unsettled questions. Amid a plethora of therapeutic options, gaps remain in our understanding about when…
In November 2008, Treatment Action Group, the Foundation for AIDS Research, and the FAIR Foundation sponsored a meeting of leading scientists in Washington, D.C., to discuss the possible avenues—and impediments—to finding a way to eliminate HIV from the body—or at…
New Links Provoke Mystery, but Research Lags By Bob Huff People with HIV may experience low-level inflammation that erodes health and shortens life spans—even after their virus is undetectable. A recent and growing worry in the AIDS treatment community concerns…
By Mark Harrington From a special plenary session titled "Looking to the Future – The Epidemic in 2031, and New Directions in AIDS Research" at the XVII International AIDS Conference in Mexico City, August 6, 2008. Twenty years ago this…
By Bob Huff The struggle for social justice is deeply woven into the fight against AIDS—and will likely continue long after AIDS has faded. At the XVII International AIDS Conference, held in Mexico City this summer, a new drama debuted…
Battling the TB/HIV Epidemic through Community Action Through advocacy workshops and by coordinating and supporting activists' advocacy efforts, TAG and ICW work together to increase community understanding of TB/HIV coinfection and enhance research, treatment, and resources to combat the two…
Why Are They Resistant to AIDS? By Richard Jefferys Since the 1980s, it has been documented that chimpanzees infected with HIV in research studies typically control viral replication and remain asymptomatic. In only a few reported cases have infected chimpanzees…
Large-Scale Vaccine Trial Nixed By Richard Jefferys NIAID's announcement that it would not support the 2,400-person PAVE100 trial left open the possibility of an even smaller trial, solely evaluating the impact on postinfection viral load set point. A little over…
By Bob Huff Better drugs are urgently needed for most of the people in the world who still lack treatment for HIV. Yet physician contentment with current treatment options in Europe and the United States may hold back research to…
Hindsight versus Foresight By Richard Jefferys While still analyzing data from the third ever AIDS vaccine efficacy trial, the field is serenaded by a chorus of opinions. On March 25, the National Institute of Allergy and Infectious Diseases (NIAID) convened…